Background Cancer patients are at a higher risk of developing severe coronavirus disease
2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccination in cancer …

… titers than healthy adults (P = 0.0004). Ongoing moderate/severe chronic GVHD (P < 0.01)
as well as rituximab administration in the year prior to vaccination (P < 0.05) correlated with …

… patients receiving TriMix alone (P = 0.0126). Finally, usVL also significantly increased at
weeks 6 and 8 (P < 0.05) in groups 4 and 5 and returned to baseline values at week 24 (Fig. 4c)…

We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants
in unimmunized infected (group 1), immunised and boosted (group 2) and infected …

… GVHD was also associated with lower NAb titers against the Omicron variant after booster
immunization (p = 0.0002; only 1 of the 10 patients with chronic GVHD had detectable NAb …

… At the time-point before ART resumption, total and integrated DNA as well as LTR-RNA were
significantly higher as compared to baseline (p < 0.0001, <0.05 and <0.05 respectively). By …

… the mRNA1273 vaccine (OR 4.5; P<0.001). Main factors associated with … P=0.006), shorter
time since transplantation (P=0.004), number of immunosuppressive drugs (per one OR 2.0, P…

Background Residents of nursing homes (NH) are at high risk of COVID-19 related morbidity
and death and may respond poorly to vaccination because of old age and frequent …

… of malaria transmission, based on the number of P. falciparum malaria cases confirmed by
both … real-time PCR assays targeting the same gene and specifically amplifying P. falciparum, …

… P < 0.05 with homologous boosted patients with cancer receiving B-cell depleting therapy.
#, P < … P < 0.05 with heterologous boosted patients with cancer receiving other hematologic …